Ramiven 150mg (Abemaciclib Tablet) 150mg

Abemaciclib works by selectively inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6). These kinases are involved in the regulation of the cell cycle. By inhibiting CDK4/6, abemaciclib prevents the progression of the cell cycle from G1 to S phase, leading to cell cycle arrest and inhibition of tumor cell proliferation. This mechanism helps to slow down the growth and spread of cancer cells.

The usual dose of Ramiven 150mg is determined by a healthcare professional based on the patient's condition, response to treatment, and other factors. It is typically taken orally, and the prescriber will set the appropriate dosage and schedule. Always follow the dosage instructions provided by your healthcare provider.

Ramiven 150mg should be avoided during pregnancy due to the potential risk of embryo-fetal toxicity. Women who are pregnant or planning to become pregnant should discuss the risks and benefits with their healthcare provider. Additionally, breastfeeding should be avoided while taking abemaciclib, as it is not known whether the drug passes into breast milk.

To order Ramiven 150mg from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets. The team will ask you to confirm your trade or institutional credentials and will then provide pricing, availability, shipping details, and the necessary import paperwork.

Ramiven 150mg is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, which is a targeted therapy for hormone receptor-positive, HER2-negative breast cancer. It is often used in combination with endocrine therapy. Compared to other treatments, such as chemotherapy or other targeted therapies, abemaciclib offers a different mechanism of action that can be beneficial for certain patients. The choice of treatment depends on various factors, including the stage of cancer, the patient's overall health, and the specific characteristics of the tumor.

Ramiven 150mg should be stored below 25°C, in the original pack, and protected from moisture. It is important to keep the medication out of reach of children and to follow the storage instructions provided with the product. Proper storage ensures the stability and effectiveness of the medication.

Ramiven 150mg is administered orally, typically in the form of tablets. The dosage and schedule are determined by a healthcare professional based on the patient's condition and response to treatment. It is important to follow the administration instructions provided by your healthcare provider and to take the medication as prescribed.

The most serious risks associated with Ramiven 150mg include interstitial lung disease/pneumonitis, hepatotoxicity, severe neutropenia, febrile neutropenia, and venous thromboembolic events. Patients should be monitored closely for these potential adverse effects, and any signs or symptoms should be reported to a healthcare provider immediately. Regular blood tests and other monitoring may be required to manage these risks.

Ramiven 150mg should not be used by individuals who are allergic to abemaciclib or any of the excipients in the formulation. It should also be avoided during pregnancy due to the potential risk of embryo-fetal toxicity. Patients with severe hepatic impairment or those taking strong CYP3A4 inducers or inhibitors should use abemaciclib with caution or avoid it altogether. Always consult a healthcare provider to determine if Ramiven 150mg is appropriate for your specific condition.